YiPSCELL

YiPSCELL is a South Korea-based private biotechnology company focused on induced pluripotent stem cell (iPSC)-based regenerative medicine. The company develops iPSC-derived cell therapies and supporting research services, including cell line production, quality control, and disease modeling. Its lead disclosed therapeutic focus is osteoarthritis/cartilage regeneration, with the program MIUChon positioned as an iPSC-derived treatment intended to repair degenerative joint tissue. YiPSCELL has also described work in disease modeling, systemic sclerosis-related applications, and artificial red blood cell research. The company appears to operate as both a therapeutic developer and a platform player built around iPSC generation, differentiation, and translational regenerative medicine capabilities.